REG - Syncona Limited - Autolus announces partial exercise of ADS option

SynconaAnnouncement

22/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221222:nRSV5430Ka&default-theme=true

RNS Number : 5430K  Syncona Limited  22 December 2022

Syncona Limited

 

Autolus Announces Partial Exercise of Underwriters' Option to Purchase
Additional ADSs

 

22 December 2022

 

Syncona Ltd, a leading healthcare company focused on creating, building and
scaling global leaders in life science, notes that its portfolio company,
Autolus Therapeutics plc ("Autolus") yesterday announced that the underwriters
of its previously announced public offering of American Depositary Shares
("ADSs") which closed on December 13, 2022, have partially exercised their
option to purchase an additional 6,927,102 ADSs, at a price per ADS of $2.00,
resulting in additional gross proceeds to Autolus of approximately $13.9
million (£11.5 million) 1  (#_ftn1) . After giving effect to the issuance of
these additional shares, which closed yesterday, Autolus has sold a total of
81,927,102 ADSs in the offering for aggregate gross proceeds of approximately
$163.9 million (£135.6 million).

 

Syncona invested approximately $28.0 million (£23.2 million) in the offering.
Following the offering, Syncona retains a stake of approximately 17.9% in
Autolus (amounting to 33,527,163 ordinary shares) which was valued at £55.5
million on 21 December 2022 according to the offering price.

 

This announcement does not constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.

The securities described above were offered by Autolus pursuant to an
effective shelf registration statement that was previously filed with the U.S.
Securities and Exchange Commission ("SEC"). A final prospectus supplement to
the accompanying prospectus describing the terms of the offering was filed
with the SEC.  The offering was made only by means of a written prospectus
and prospectus supplement that form a part of the registration statement,
which, for the avoidance of doubt, does not constitute a "prospectus" for the
purposes of the Regulation (EU) 2017/1129 and has not been reviewed by any
competent authority in any member state in the European Economic Area. Copies
of the final prospectus supplement and the accompanying prospectus relating to
the offering may be obtained for free from either of the joint book-running
managers for the offering, Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by telephone at +1 877 821 7388 or by email at
Prospectus_Department@Jefferies.com; William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL
60606, by telephone at (800) 621-0687, or by email at
prospectus@williamblair.com; or Wells Fargo Securities, LLC, Attention: Equity
Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at
(800) 326-5897 or email a request to cmclientsupport@wellsfargo.com.

 ENDS 

Enquiries

Syncona Ltd

 

Annabel Clark / Fergus Witt

Tel: +44 (0) 20 3981 7940

 

FTI Consulting

 

Ben Atwell / Natalie Garland-Collins / Julia Bradshaw / Tim Stamper

Tel: +44 (0) 20 3727 1000

 

 

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by
creating and building companies to deliver transformational treatments to
patients in areas of high unmet need.

Our strategy is to create, build and scale companies around exceptional
science to create a diversified portfolio of 20-25 globally leading healthcare
businesses, across development stage and therapeutic areas, for the benefit of
all our stakeholders. We focus on developing treatments for patients by
working in close partnership with world-class academic founders and management
teams. Our balance sheet underpins our strategy enabling us to take a
long-term view as we look to improve the lives of patients with no or poor
treatment options, build sustainable life science companies and deliver strong
risk-adjusted returns to shareholders.

 

 

About Autolus

 

Autolus is a clinical-stage biopharmaceutical company developing
next-generation, programmed T cell therapies for the treatment of cancer.
Using a broad suite of proprietary and modular T cell programming
technologies, Autolus is engineering precisely targeted, controlled and highly
active T cell therapies that are designed to better recognize cancer cells,
break down their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information, please
visit www.autolus.com.

 1  (#_ftnref1) All exchange rates taken at 21 December 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUFEIEFFEESEEE